Erratum to: Increasing sex differences in the use of cardiac resynchronization therapy with or without implantable cardioverterdefibrillator (European Heart Journal (2017) DOI: 10.1093/eurheartj/ehw598);Increasing sex differences in the use of cardiac resynchronization therapy with or without implantable cardioverter-defibrillator

European Heart Journal

Volumn 38, Issue 19, 2017, Pages 1485-1494

  Chatterjee, Neal A ^a   Borgquist, Rasmus ^b   Chang, Yuchiao ^a   Lewey, Jennifer ^c   Jackson, Vicki A ^a   Singh, Jagmeet P ^a   Metlay, Joshua P ^a   Lindvall, Charlotta ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b LUND UNIVERSITY   (Sweden)

^c Department of Medicine   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Cardiac resynchronization therapy; Implantable cardioverter defibrillator; Sex disparities

Indexed keywords

ADULT; AGED; ARTICLE; ASSOCIATION; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL FEATURE; COMORBIDITY; CROSS-SECTIONAL STUDY; FEMALE; HEART ARREST; HEART VENTRICLE ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SECONDARY PREVENTION; SEX DIFFERENCE; TREATMENT RESPONSE; ADOLESCENT; AGE DISTRIBUTION; COMPARATIVE STUDY; HEALTH CARE DISPARITY; HEART FAILURE; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MIDDLE AGED; SEX RATIO; UNITED STATES; UTILIZATION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CARDIAC RESYNCHRONIZATION THERAPY; CROSS-SECTIONAL STUDIES; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HEALTHCARE DISPARITIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; SEX DISTRIBUTION; UNITED STATES; YOUNG ADULT;

EID: 85039066777     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehx029     Document Type: Erratum

References (32)

1. Leyva F, Nisam S, Auricchio A. 20 years of cardiac resynchronization therapy. J Am Coll Cardiol 2014;64:1047-1058.
2. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. Longer-Term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J 2006;27:1928-1932.
3. Solomon SD, Foster E, Bourgoun M, Shah A, Viloria E, Brown MW, Hall WJ, Pfeffer MA, Moss AJ. Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: multicenter automatic defibrillator implantation trial: cardiac resynchronization therapy. Circulation 2010;122:985-992.
4. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekval TM, Spaulding C, Van Veldhuisen DJ. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;36:2793-2867.
5. Lindvall C, Chatterjee NA, Chang Y, Chernack B, Jackson VA, Singh JP, Metlay JP. National trends in the use of cardiac resynchronization therapy with or without implantable cardioverter-defibrillator. Circulation 2016;133:273-281.
6. Steinberg BA, Al-Khatib SM, Edwards R, Han J, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Steinman R, Dorian P, Hallstrom A, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Inoue LY, Sanders GD. Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: Results from a combined analysis of 4 randomized clinical trials. JACC Heart Fail 2014;2:623.
7. Chatterjee NA, Singh JP. Cardiac resynchronization therapy: past, present, and future. Heart Fail Clin 2015;11:287-303.
8. Hsu JC, Solomon SD, Bourgoun M, McNitt S, Goldenberg I, Klein H, Moss AJ, Foster E. Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: The MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy) study. J Am Coll Cardiol 2012;59:2366-2373.
9. Al-Khatib SM, Hellkamp AS, Hernandez AF, Fonarow GC, Thomas KL, Al-Khalidi HR, Heidenreich PA, Hammill S, Yancy C, Peterson ED. Trends in use of implantable cardioverter-defibrillator therapy among patients hospitalized for heart failure: have the previously observed sex and racial disparities changed over time? Circulation 2012;125:1094-1101.
10. HCUP National Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP). 2006-2012. Agency for Healthcare Research and Quality, Rockville, MD. www.hcup-us.ahrq.gov/nisoverview.jsp (20 October 2015).
11. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998;36:8-27.
12. HCUP Comorbidity Software. Healthcare Cost and Utilization Project (HCUP). 2008. Agency for Healthcare Research and Quality, Rockville, MD. www.hcupus.ahrq.gov/toolssoftware/comorbidity/comorbidity.jsp (20 October 2015).
13. Bilchick KC, Stukenborg GJ, Kamath S, Cheng A. Prediction of mortality in clinical practice for medicare patients undergoing defibrillator implantation for primary prevention of sudden cardiac death. J Am Coll Cardiol 2012;60:1647-1655.
14. van Rees JB, Borleffs CJ, van Welsenes GH, van der Velde ET, Bax JJ, van Erven L, Putter H, van der Bom JG, Schalij MJ. Clinical prediction model for death prior to appropriate therapy in primary prevention implantable cardioverter defibrillator patients with ischaemic heart disease: The FADES risk score. Heart 2012;98:872-877.
15. Healey JS, Hohnloser SH, Exner DV, Birnie DH, Parkash R, Connolly SJ, Krahn AD, Simpson CS, Thibault B, Basta M, Philippon F, Dorian P, Nair GM, Sivakumaran S, Yetisir E, Wells GA, Tang AS. Cardiac resynchronization therapy in patients with permanent atrial fibrillation: Results from the Resynchronization for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail 2012;5:566-570.
16. Mathew J, Katz R, St John Sutton M, Dixit S, Gerstenfeld EP, Ghio S, Gold MR, Linde C, Shlipak MG, Deo R. Chronic kidney disease and cardiac remodelling in patients with mild heart failure: Results from the REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE) study. Eur J Heart Fail 2012;14:1420-1428.
17. Zusterzeel R, Spatz ES, Curtis JP, Sanders WE, Selzman KA, Pina IL, Bao H, Ponirakis A, Varosy PD, Masoudi FA, Canos DA, Strauss DG. Cardiac resynchronization therapy in women versus men: observational comparative effectiveness study from the National Cardiovascular Data Registry. Circ Cardiovasc Qual Outcomes 2015;8(2 Suppl 1):S4-11.
18. Bogale N, Priori S, Gitt A, Alings M, Linde C, Dickstein K. The European cardiac resynchronization therapy survey: patient selection and implantation practice vary according to centre volume. Europace 2011;13:1445-1453.
19. Zeitler EP, Hellkamp AS, Schulte PJ, Fonarow GC, Hernandez AF, Peterson ED, Sanders GD, Yancy CW, Al-Khatib SM. Comparative effectiveness of implantable cardioverter defibrillators for primary prevention in women. Circ Heart Fail 2016;9:e002630.
20. Marijon E, Leclercq C, Narayanan K, Boveda S, Klug D, Lacaze-Gadonneix J, Defaye P, Jacob S, Piot O, Deharo JC, Perier MC, Mulak G, Hermida JS, Milliez P, Gras D, Cesari O, Hidden-Lucet F, Anselme F, Chevalier P, Maury P, Sadoul N, Bordachar P, Cazeau S, Chauvin M, Empana JP, Jouven X, Daubert JC, Le Heuzey JY. Causes-of-death analysis of patients with cardiac resynchronization therapy: An analysis of the CeRtiTuDe cohort study. Eur Heart J 2015;36: 2767-2776.
21. Lam SK, Owen A. Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-Analysis of randomised controlled trials. BMJ 2007;335:925.
22. Chatterjee NA, Roka A, Lubitz SA, Gold MR, Daubert C, Linde C, Steffel J, Singh JP, Mela T. Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: A meta-Analysis and systematic review. Eur Heart J 2015;36:2780-2789.
23. Raphael CE, Finegold JA, Barron AJ, Whinnett ZI, Mayet J, Linde C, Cleland JG, Levy WC, Francis DP. The effect of duration of follow-up and presence of competing risk on lifespan-gain from implantable cardioverter defibrillator therapy: Who benefits the most? Eur Heart J 2015;36:1676-1688.
24. Dickstein K, Bogale N, Priori S, Auricchio A, Cleland JG, Gitt A, Limbourg T, Linde C, van Veldhuisen DJ, Brugada J. The European cardiac resynchronization therapy survey. Eur Heart J 2009;30:2450-2460.
25. Marijon E, Leclercq C, Narayanan K, Boveda S, Klug D, Lacaze-Gadonneix J, Defaye P, Jacob S, Piot O, Deharo JC, Perier MC, Mulak G, Hermida JS, Milliez P, Gras D, Cesari O, Hidden-Lucet F, Anselme F, Chevalier P, Maury P, Sadoul N, Bordachar P, Cazeau S, Chauvin M, Empana JP, Jouven X, Daubert JCL, Heuzey JY. Causes-of-death analysis of patients with cardiac resynchronization therapy: An analysis of the CeRtiTuDe cohort study. Eur Heart J 2015;36:2767-2776.
26. Kramer DB, Reynolds MR, Normand SL, Parzynski CS, Spertus JA, Mor V, Mitchell SL. Hospice use following implantable cardioverter-defibrillator implantation in older patients: Results from the NCDR(R). Circulation 2016;133:2030-2037.
27. Kober L, Thune JJ, Nielsen JC, Haarbo J, Videbaek L, Korup E, Jensen G, Hildebrandt P, Steffensen FH, Bruun NE, Eiskjaer H, Brandes A, Thogersen AM, Gustafsson F, Egstrup K, Videbaek R, Hassager C, Svendsen JH, Hofsten DE, Torp-Pedersen C, Pehrson S. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 2016;375:1221.
28. Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, Reddy RK, Marchlinski FE, Yee R, Guarnieri T, Talajic M, Wilber DJ, Fishbein DP, Packer DL, Mark DB, Lee KL, Bardy GH. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 2008;359:1009-1017.
29. Brunner-La Rocca HP, Rickenbacher P, Muzzarelli S, Schindler R, Maeder MT, Jeker U, Kiowski W, Leventhal ME, Pfister O, Osswald S, Pfisterer ME, Rickli H. End-of-life preferences of elderly patients with chronic heart failure. Eur Heart J 2012;33:752-759.
30. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, Cleland J, Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW, Leclercq C, Linde C, Mont L, Padeletti L, Sutton R, Vardas PE, Guidelines ESCCfP, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Document R, Kirchhof P, Blomstrom-Lundqvist C, Badano LP, Aliyev F, Bansch D, Baumgartner H, Bsata W, Buser P, Charron P, Daubert JC, Dobreanu D, Faerestrand S, Hasdai D, Hoes AWL, Heuzey JY, Mavrakis H, McDonagh T, Merino JL, Nawar MM, Nielsen JC, Pieske B, Poposka L, Ruschitzka F, Tendera M, Van Gelder IC, Wilson CM. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in Collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J 2013;34:2281-2329.
31. Quan H, Parsons GA, Ghali WA. Validity of information on comorbidity derived rom ICD-9-CCM administrative data. Med Care 2002;40:675-685.
32. Al Kazzi ES, Lau B, Li T, Schneider EB, Makary MA, Hutfless S. Differences in the prevalence of obesity, smoking and alcohol in the United States nationwide inpatient sample and the behavioral risk factor surveillance system. PLoS One 2015;10:e0140165.